BeOne Medicines (ONC) Interest & Investment Income (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Interest & Investment Income of $27.7 million for Q1 2026, up 115.28% year-over-year from $12.8 million in Q1 2025, and up 115.28% quarter-over-quarter from $12.8 million in Q1 2025.
BeOne Medicines (ONC) Interest & Investment Income (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Interest & Investment Income for 4 consecutive years, with $27.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income rose 115.28% year-over-year to $27.7 million; the TTM figure through Mar 2026 stood at $41.0 million (up 196.67% YoY), while the FY2025 annual figure was $70.5 million, up 1.24% from the prior year.
- Interest & Investment Income rose to $27.7 million in Q1 2026 per ONC's latest filing, from $12.8 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $27.7 million in Q1 2026 and bottomed at $12.8 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Roivant Sciences | 26.20 Bn | 26.20 Bn | 1.16 Mn | 36.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.90 Mn |
| Mar 31, 2026 | 27.66 Mn |
| Mar 31, 2025 | 12.85 Mn |
| Sep 30, 2016 | 209,000.00 |
| Jun 30, 2016 | 262,000.00 |
| Mar 31, 2016 | 494,000.00 |
| Sep 30, 2015 | 760,000.00 |
| Jun 30, 2015 | 409,000.00 |
| Mar 31, 2015 | 117,000.00 |